Bolag
Scandinavian ChemoTech är ett svenskt bolag som utvecklar och marknadsför medicinteknologi baserad på elektrokemoterapi för behandling av cancer. Bolaget erbjuder system och lösningar till kliniker inom onkologi och veterinärmedicin och har verksamhet på internationella marknader, bland annat i Indien och Sydostasien. Bolaget grundades 2015 och har sitt huvudkontor i Lund, Sverige.
Bolagets senaste flöde, utan extra fluff.
Scandinavian ChemoTech AB (publ) (the “Company”) today announces that, based on information disclosed in the Company’s press releases published on Tuesday, March 31, ahead of the notice of the Annual General Meeting, Nasdaq Stockholm has communicated its preliminary assessment regarding the Company’s proposed strategic changes.
Retransmission of the press release that was published, with the associated MAR label, on April 1st, 2026 at 16:50. Scandinavian ChemoTech’s Animal Care continues its strong commercial momentum, delivering its best first quarter in the company’s history in Q1 2026, with sales amounting to approx. 299,000 USD compared to approx. 235,000 USD in Q1 2025, a growth of 27%. This performance marks a strong start to 2026 and reinforces the positive growth trajectory established throughout 2025. It also demonstrates the increasing market acceptance of the company’s veterinary oncology offering and the continued success of its commercial strategy.
Scandinavian ChemoTech’s Animal Care continues its strong commercial momentum, delivering its best first quarter in the company’s history in Q1 2026, with sales amounting to approx. 299,000 USD compared to approx. 235,000 USD in Q1 2025, a growth of 27%. This performance marks a strong start to 2026 and reinforces the positive growth trajectory established throughout 2025. It also demonstrates the increasing market acceptance of the company’s veterinary oncology offering and the continued success of its commercial strategy.
NOT FOR DISCLOSURE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER STATE OR JURISDICTION WHERE DISCLOSURE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES UNDER APPLICABLE LAW. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. The board of directors of Scandinavian ChemoTech AB (publ) (“ChemoTech” or the “Company”) has received a proposal from the Company’s shareholder Martin Jerndal on a directed issue of a maximum of 761,191 class A shares (the “Directed Issue”) to be resolved by the Annual General Meeting 2026 (the “AGM”). The Directed Issue amounts to approximately SEK 2.55 million and the Company’s CEO, members of the board and current investors are proposed to subscribe for the new class A shares should the AGM approve the resolution. The Company has further been evaluating various strategic directions for the Company. As a result of that evaluation, the board of directors has decided to propose that the Company's business is extended to include consulting services in business development and organization within veterinary and human medicine sectors, as well as asset management activities. The proposed changes represent an expansion of ChemoTech's existing business rather than a fundamental change in business direction. The Company's core medical technology activities will continue, with consulting services and asset management providing additional complementary capabilities. This expansion builds upon ChemoTech's existing expertise and relationships within the medical technology sector, extending the Company's capabilities to provide broader business development and strategic support services. To better reflect this expanded scope of activities, the Company also intends to change the Company’s name to Neem's Hill AB. To facilitate this transition, the board of directors of ChemoTech intends to propose amendments of the Company’s articles of association during the AGM to be held on 5 May 2026. The notice to the AGM will be published through a separate press release.
Scandinavian Chemotech proudly announces the upgrade of its subsidiary’s Central Drugs Standard Control Organization (CDSCO) approval for IQwave™ from voluntary registration to a full license under the Medical Devices Rules (MDR) 2017. This approval grants ChemoTech’s subsidiary to market and sell IQwave systems in India.
Retransmission of the press release that was published, with the associated MAR label, on February 18th, 2026 at 20:50. Scandinavian ChemoTech today announced that a clinical study conducted by Prof. Cathrine T. Fjordbakk, DVM, PhD, Diplomate ECVS, Diplomate ECVSMR, Professor in Equine Surgery at the Norwegian University of Life Sciences (NMBU), will be presented at the annual scientific meeting of the European College of Veterinary Surgeons (ECVS), in Liverpool, July 2026.The study evaluates the clinical use of Tumour Specific Electroporation™️ (TSE) within the vetIQure™️ platform for equine sarcoid management.
Scandinavian ChemoTech today announced that a clinical study conducted by Prof. Cathrine T. Fjordbakk, DVM, PhD, Diplomate ECVS, Diplomate ECVSMR, Professor in Equine Surgery at the Norwegian University of Life Sciences (NMBU), will be presented at the annual scientific meeting of the European College of Veterinary Surgeons (ECVS), in Liverpool, July 2026.The study evaluates the clinical use of Tumour Specific Electroporation™️ (TSE) within the vetIQure™️ platform for equine sarcoid management.
The report is attached to this press release and can also be downloaded from the company's website.
Kentucky - US, VQ Animal Care Inc, the U.S. subsidiary of Scandinavian ChemoTech, today announced the receipt of its first U.S. order from an internationally renowned equine clinic in Kentucky at the heart of America’s equine industry with operations across multiple locations in US. This agreement marks VQ Animal Care’s first commercial collaboration with an equine clinic in the United States, underscoring the company’s expanding global footprint in advanced veterinary oncology solutions.